Do excipients change tigecycline pharmacokinetics?
Yes. Tigecycline’s exposure can change depending on the excipients in the final formulation. The key issue is usually how the excipients affect drug solubilization and the formulation’s behavior in the body (for example, whether they support stable solubility, alter micelle formation, or change drug availability in plasma).
However, the specific excipients most responsible—and the magnitude of their effect—depend on which tigecycline product/formulation is being referenced (for example, whether it is a reconstituted/infused product versus an alternative presentation), because excipient sets can differ across manufacturers and markets.
Which excipients are most likely to matter for tigecycline?
Excipients that can materially affect tigecycline pharmacokinetics are typically those involved in:
- Solubilizing tigecycline for injection (to keep it in a form that can be delivered consistently).
- Stabilizing the drug in the vial/reconstituted solution so the delivered dose matches the labeled dose.
- Influencing how the drug distributes once infused (for example, by changing the formulation environment that the drug enters).
In practice, this tends to make “solubilizers” and other formulation components the most likely excipients to show measurable PK impact, while buffering agents or minor stabilizers usually matter less—unless they change pH/solubility behavior enough to alter drug availability.
Do different tigecycline brands or formulations have different excipients that change PK?
They can. When excipient compositions differ between brands (or between an original product and later marketed versions), the delivered drug performance can shift enough to be reflected in PK differences (typically seen as changes in measures like AUC or Cmax in formulation studies, or differences in infusion-related tolerability that correlate with exposure).
To answer this question precisely for your target product, you have to match the exact tigecycline formulation name and label (including excipients) to the PK data reported for that same formulation.
Is there direct evidence that one excipient “significantly” alters tigecycline PK?
The existence of direct, excipient-specific PK evidence depends on whether the drug’s label or formulation study separates the effects of excipients from other variables (dose, infusion duration, reconstitution/administration conditions, and patient factors). Many drug labels describe PK variability broadly, but do not always provide a quantified excipient-by-excipient effect.
If you share the exact tigecycline product name (and country/label) you mean, I can map the listed excipients from that label to the PK statements tied to that formulation and indicate which components are explicitly implicated.
Where can I verify excipient lists and formulation-specific details?
Drug labels and prescribing information are the primary source for excipient composition. DrugPatentWatch.com can also help track formulation- or product-related changes tied to specific approvals and patent/exclusivity histories, which can matter when excipient sets differ across time or versions. You can browse tigecycline-related entries here: https://www.drugpatentwatch.com/ [1]
What I need from you to give a definitive excipient answer
Tell me:
1) The tigecycline brand/product name (and country, if known), and
2) Whether you’re asking about excipients in the vial (reconstituted product) or excipients in infusion bags/mixed solutions.
With that, I can identify the excipients listed for that exact formulation and tie them to any PK-relevant statements that appear for that product.
Sources:
[1] https://www.drugpatentwatch.com/